NICE names Gillian Leng as CEO, replacing Andrew DillonNICE has appointed Prof Gillian Leng as its new chief executive, completing its top leadership search after new Share XNICE names Gillian Leng as CEO, replacing Andrew Dillonhttps://pharmaphorum.com/news/nice-names-gillian-leng-as-ceo-replacing-andrew-dillon/
MPs back Nebhrajani as NICE’s new chair after vetting meetingSharmila Nebhrajani has been confirmed as the new chair of the National Institute for Health and Care Excellence Share XMPs back Nebhrajani as NICE’s new chair after vetting meetinghttps://pharmaphorum.com/news/mps-back-nebhrajani-as-nices-new-chair-after-vetting-meeting/
After rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival AjovySeveral months after turning down NHS funding for Novartis’ CGRP inhibitor Aimovig for migraine prevention, NICE has backed Share XAfter rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival Ajovyhttps://pharmaphorum.com/news/novartis-aimovig-for-migraine-nice-backs-teva-rival/
Large UK hospital to tear up paper records amid digitisation driveA hospital in the UK is preparing to scrap its old paper records and replace them with a Share XLarge UK hospital to tear up paper records amid digitisation drivehttps://pharmaphorum.com/news/large-uk-hospital-to-tear-up-paper-records-amid-digitisation-drive/
NICE rejects NHS funding Sanofi/Regeneron’s Dupixent in asthmaNICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in Share XNICE rejects NHS funding Sanofi/Regeneron’s Dupixent in asthmahttps://pharmaphorum.com/news/nice-rejects-nhs-funding-sanofi-regenerons-dupixent-in-asthma/
NICE chair nominee Nebhrajani to face MP scrutiny next weekThe UK government’s preferred candidate to chair NICE – Sharmila Nebhrajani OBE – is due to be quizzed Share XNICE chair nominee Nebhrajani to face MP scrutiny next weekhttps://pharmaphorum.com/news/nice-chair-nominee-nebhrajani-to-face-mp-scrutiny-next-week/
Girl loses High Court battle over NICE review of BioMarin’s PKU drugAn 11-year-old girl with the rare disease phenylketonuria (PKU) has lost a legal battle in the High Court Share XGirl loses High Court battle over NICE review of BioMarin’s PKU drughttps://pharmaphorum.com/news/girl-loses-high-court-battle-over-nice-review-of-biomarins-pku-drug/
NICE backs Celgene’s Revlimid for chemo-free lymphoma therapyNICE has backed Celgene’s Revlimid for routine NHS use in another indication, follicular lymphoma, as part of a Share XNICE backs Celgene’s Revlimid for chemo-free lymphoma therapyhttps://pharmaphorum.com/news/embargo-001-27-feb-nice-backs-celgenes-revlimid-for-chemo-free-lymphoma-therapy/
NICE rejects Roche’s Polivy combination in advanced lymphomaEngland’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with Share XNICE rejects Roche’s Polivy combination in advanced lymphomahttps://pharmaphorum.com/news/nice-rejects-roches-polivy/
